• Yousef Zakharia, Kais Zakharia, and Olivier Rixe.
• University of Iowa Division of Hematology/Oncology and Holden Comprehensive Cancer Center , Iowa City, Iowa, USA yousef-zakharia@uiowa.edu.
• Expert Opin Drug Discov. 2015 Jan 1; 10 (8): 925-35.

IntroductionBased on extensive preclinical data and abundant evidence for clinical activity, vascular endothelial growth factor receptor (VEGFR) inhibitors are currently standard of care for metastatic renal cell carcinoma (mRCC). Axitinib is one of the most selective molecules in the class of anti-angiogenic agents, which confers an optimal profile between its safety and anti-cancer activity spectrum.Area CoveredIn this review, the authors discuss the different stages that lead to the approval of axitinib in the clinic as well as the current perspectives for its clinical use with other promising therapies in mRCC such as immune checkpoint inhibitors and vaccines.Expert OpinionIn 2015, axitinib has emerged as one of the major agents used in mRCC. Based on robust preclinical data, this highly specific VEGFR inhibitor continues to be evaluated in different indications, including the adjuvant setting but also sequential administration with other molecularly targeted agents or combinations with immune therapies.

37 keywords...

hide…